Companies that produce medications and diagnostic technologies for the treatment of illnesses and medical conditions make up the biotechnology sector. Before being approved by the US Food and Drug Administration, many items must undergo extensive, costly, and time-consuming testing (FDA). This implies that investors may have to wait years to find out if a medicine under development is profitable. Smaller start-ups with recent traction coexist with huge, well-established enterprises in this industry, which aims to produce a wide range of pharmaceuticals and technology. Many biotech firms have completely switched their emphasis or incorporated COVID-19 vaccines and therapies into their development pipelines.
Royalty Pharma PLC
Royalty Pharma is a biopharmaceutical product investment firm focused on late-stage development. To develop therapies, the firm partners with biotechnology companies of all sizes, research hospitals, academic institutions, and research hospitals. Its pharmaceutical investment portfolio comprises both commercial and development-stage prospects. In Q2 2021, the company’s operating income increased by 82.2 percent year over year, in addition to robust EPS growth.
Sage Therapeutics Inc.
Sage Therapeutics is a company that develops medicines for illnesses of the central nervous system, such as schizophrenia and major depressive disorder. Sage announced on September 15 that the FDA had given its medicine SAGE-718 Fast Track Designation for development as a possible therapy for Huntington’s disease, a hereditary illness that affects the brain.
Ocugen Inc.
Ocugen is a biopharmaceutical business that specializes in treating blindness and other retinal illnesses. If we compare the same quarter to the previous year, the company’s net loss increased considerably as research and development spending skyrocketed. It did not generate any money. Despite this, COVAXIN, the company’s COVID-19 vaccine, received good Phase 3 clinical trial results from partner Bharat Biotech of India.
Maravai LifeSciences Holdings Inc.
Maravai LifeSciences Holdings is a biotechnology firm. The firm develops pharmacological treatments, diagnostics, and vaccines for the treatment of a variety of illnesses through its subsidiaries. Maravai LifeSciences Holdings’ net income climbed 35-fold in Q2 2021, while sales expanded more than four-fold. The company’s Nucleic Acid Production division grew at a rapid pace, which accounted for the majority of the revenue rise.
Agios Pharmaceuticals Inc.
Agios is a pharmaceutical business that develops medicines for illnesses that are genetically specified, such as hemolytic anemias and sickle cell disease. The business reported in mid-August that the FDA has accepted its New Drug Application (NDA) for mitapivat for the treatment of people with pyruvate kinase deficiency, a chronic, life-long hemolytic anemia.
Aclaris Therapeutics Inc.
Aclaris Therapeutics is a clinical-stage biopharmaceutical business focusing on the development of medications to treat immuno-inflammatory illnesses.
CRISPR Therapeutics AG
CRISPR Therapeutics AG is a Swiss firm that develops gene-based therapeutics for cancer, regenerative medicine, and hemoglobinopathy illnesses. CRISPR’s rapid revenue increase in Q2 2021 was almost completely powered by its partnership with Vertex Pharmaceuticals Inc. (VRTX). As part of the conditions of the agreement in developing CTX001, a gene-based medicine, Vertex paid CRISPR a $900 million upfront payment in June.
